Previous 10 | Next 10 |
2023-08-02 07:59:40 ET More on Teva Pharmaceutical Teva Pharmaceutical's Remarkable Growth In 2023: A Success Story Teva Pharmaceutical: Lacking Capabilities For Strategic Investments Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence Seek...
2023-08-02 07:03:13 ET Teva Pharmaceutical press release ( NYSE: TEVA ): Q2 Non-GAAP EPS of $0.56 beats by $0.03 . Revenue of $3.9B (+2.6% Y/Y) beats by $180M . Cash flow generated from operating activities of $324 million. Free cash flow of $632 million. ...
Revenues of $3.9 billion GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56 Cash flow generated from operating activities of $324 million Free cash flow of $632 million AUSTEDO ® U.S. revenues of $308 million 2023 revenues outlook revised to $15.0-$15.4 bi...
2023-08-01 14:30:32 ET Amid an on-going shortage of the ADHD drug Adderall (mixed amphetamine salts), the US FDA and DEA are asking manufacturers to step up production. The nationwide shortage has been happening since at least October 2022 when the FDA issued an advisory , specifica...
2023-07-31 03:07:28 ET Summary Vanda Pharmaceuticals' Q2 2023 financial performance shows a decline in sales due to generic competition, particularly for Hetlioz. VNDA is facing challenges with negative earnings per share projections and declining sales, leading to uncertainty abo...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva's US headquarters in Parsippany, NJ. This press release featu...
2023-07-26 15:04:29 ET The World Health Organization updated its Essential Medicines List on Wednesday without adding a class of weight loss medications called glucagon-like peptide-1 (GLP-1) receptor agonists as a treatment for obesity. The list designed to guide state procurement deci...
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in generic and innovative medicines and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
2023-07-23 04:30:00 ET Summary Patient Capital Management are long-term, contrarian, value investors focusing on growing wealth through Time, not Timing. We operate with the singular purpose of serving clients and helping them enhance their long term investment returns. Patient Ca...
2023-07-20 10:43:40 ET Summary On August 2, 2023, Teva Pharmaceutical, one of the world's top generic drug manufacturers, will publish its financial report for the second quarter of 2023. The company has launched generic versions of several medicines and is conducting phase 2 tria...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...